“Global Rosacea Treatment Market is anticipated to surpass USD 2 Billion by 2020”, says Visiongain

07 November 2019
Pharma

Visiongain has launched a new pharma report “Rosacea Treatment Market Report 2020-2030” Prospects by Drug Class (Antibiotics, Alpha Agonists, Retinoids, Corticosteroids, Antihypertensive Agents, Other Drug Classes), Mode Of Administration (Topical, Oral), And Geography.

Global rosacea treatment market is projected to grow on account of growing disease prevalence, advancement in formulation of drugs, and shift towards combination therapies among other factors. The global market is projected to grow at a lucrative CAGR of ~8% and anticipated to surpass USD 2 Billion by 2020.

The strong rosacea therapy drug pipeline is the primary factor driving growth in the demand for rosacea therapy during the forecast period. Numerous pharmaceutical companies are performing comprehensive research and development in the development of effective treatment options for rosacea. A variety of these drugs are being evaluated in their stage II and phase II stages. Therefore, during the forecast period, these phase II and phase III drugs are highly likely to enter the market. The addition of these molecules would fuel the growth of the rosacea treatment market and drive the growth of the industry globally.

One of the major trends in the market for rosacea treatment is the change to a variety of drugs utilizing two or three active rosacea treatments. This combination therapy reduces initial prominent symptoms, prevents relapse when oral therapy is discontinued and maintains control over the long term.

Worldwide, Rosacea affects more than 400 million people, yet it remains an undiagnosed disease. The prevalence of the global disease is estimated at 5%. People with light / fair skin appear to be more prone to this disease, especially women. Because of several differences in the presentation, the condition is often misdiagnosed as acne.

Due to multiple patent expiries and off-label use of drugs, the industry is facing high generic penetration. Some acne drugs are used to treat rosacea, such as azelaic acid, sulfur agents, and benzoyl peroxide. While the treatments available are mostly oral or topical, there is a significant paradigm shift as treatment choices are gradually inclined to combination therapies for more effective outcomes.

The FDA and other agencies' approvals for rosacea therapeutics have resulted in a lot of market enthusiasm. In August 2013, the FDA approved a topical form of alpha-2 agonist brimonidine for the treatment of rosacea-related erythema. In 2017, for chronic facial erythema associated with rosacea in adults, another topical alpha agonist, oxymetazoline, was approved. The FDA has approved topical ivermectin (Soolantra) for the treatment of rosacea inflammatory lesions. RHOFADE (Oxymetazoline Hydrochloride) cream was approved by FDA in the year 2017.

In the year 2018; North America dominated the global rosacea treatment market owing to growing government expenditure on the medical and pharmaceutical sector every year and social awareness campaigns across the United States and Canada. According to the National Rosacea Society estimates, approximately 16 million Americans are suffering from rosacea. Because of favorable regulatory requirements, which drive demand for this market, the companies also prefer to release their products first in the United States.

It is projected that the Asia Pacific rosacea treatment market would experience the fastest growth over the forecast period owing to factors such as growing awareness, growing healthcare expenditure and government support.

Some of the major players operating in this industry are Allergan plc, Bausch Health Companies Inc., Bayer AG, Foamix Pharmaceuticals Ltd., Janssen Pharmaceuticals, Inc., Mylan N.V., Nestlé Skin Health (Galderma S.A.), Pfizer Inc., Sol-Gel Technologies, SONOMA PHARMACEUTICALS, INC., Teva Pharmaceuticals Company, Aclaris Therapeutics, Amorepacific Corporation, Hovione FarmaCiencia SA, Leo Pharma Inc., and PRUGEN PHARMACEUTICALS among other prominent players.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Biological API Manufacturing Services Market Report 2021-2031

Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.

08 January 2021

Read

Visiongain Publishes Anaesthesia & Respiratory Devices Market Report 2020-2030

The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.

07 January 2021

Read

Visiongain Publishes Inactivated Vaccines Market Report 2020-2030

Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.

07 January 2021

Read

Visiongain Publishes Human Microbiome Therapeutics Market Report 2021-2031

The potential of microbiome-based drugs as novel treatments to address the unmet needs for many diseases has contributed intensively to the rapid emergence of many investors in this area. Currently, no regulatory framework exists and no drugs have received FDA approval. However, there are several preclinical and clinical-stage companies working with various approaches to develop microbiome-based therapies.

06 January 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever